Abstract：
OBJECTIVE: To evaluate literature evidences about the efficacy and safety of anti-angiogenesis agents plus chemoradiotherapy versus chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
METHODS: The relevant literature was systematically searched from the date of establishment to April 2023 in PubMed, Embase, Web of Science, The Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biological Medicine, Wanfang and VIP database. Search terms included: Nasopharyngeal Neoplasms, Angiogenesis inhibitors, Endostar, Anlotinib, Apatinib, Bevacizumab, Sunitinib, Pazopanib, Chemoradiotherapy. The literature was strictly screened according to the inclusion and exclusion criteria, and 8 eligible studies were finally included in our meta-analysis (4 randomized controlled trials and 4 retrospective studies).
RESULTS: A total of 642 patients were included, with 316 in the anti-angiogenesis agents plus chemoradiotherapy group and 326 in the chemoradiotherapy group. The results of our meta-analysis showed that compared with chemoradiotherapy group, the complete response rate (RR = 1.35, 95% CI 1.05-1.74, P = 0.02), objective response rate (RR = 1.26, 95% CI 1.12-1.43, P = 0.0002) in the anti-angiogenesis agents plus chemoradiotherapy group were significantly improved. In terms of safety, there was a higher incidence of cardiac arrhythmia (RR = 3.63, 95% CI 1.16-11.37, P = 0.03) and hypertension (RR = 1.85, 95% CI 1.04-3.27, P = 0.004) in the anti-angiogenesis agents plus chemoradiotherapy group, while no statistically significant differences were reported in other adverse reactions (all P > 0.05).
CONCLUSIONS: Compared with chemoradiotherapy, anti-angiogenesis agents plus chemoradiotherapy could bring more benefits in terms of short-term efficacy, particularly by notably improving both complete response rate and objective response rate, and overall adverse reactions were acceptable. Anti-angiogenesis agents plus chemoradiotherapy may provide a promising direction for the treatment of locally advanced nasopharyngeal carcinoma.
BACKGROUND: https://inplasy.com/inplasy-2023-8-0076/ , registration number INPLASY202380076.
METHODS: The relevant literature was systematically searched from the date of establishment to April 2023 in PubMed, Embase, Web of Science, The Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biological Medicine, Wanfang and VIP database. Search terms included: Nasopharyngeal Neoplasms, Angiogenesis inhibitors, Endostar, Anlotinib, Apatinib, Bevacizumab, Sunitinib, Pazopanib, Chemoradiotherapy. The literature was strictly screened according to the inclusion and exclusion criteria, and 8 eligible studies were finally included in our meta-analysis (4 randomized controlled trials and 4 retrospective studies).
RESULTS: A total of 642 patients were included, with 316 in the anti-angiogenesis agents plus chemoradiotherapy group and 326 in the chemoradiotherapy group. The results of our meta-analysis showed that compared with chemoradiotherapy group, the complete response rate (RR = 1.35, 95% CI 1.05-1.74, P = 0.02), objective response rate (RR = 1.26, 95% CI 1.12-1.43, P = 0.0002) in the anti-angiogenesis agents plus chemoradiotherapy group were significantly improved. In terms of safety, there was a higher incidence of cardiac arrhythmia (RR = 3.63, 95% CI 1.16-11.37, P = 0.03) and hypertension (RR = 1.85, 95% CI 1.04-3.27, P = 0.004) in the anti-angiogenesis agents plus chemoradiotherapy group, while no statistically significant differences were reported in other adverse reactions (all P > 0.05).
CONCLUSIONS: Compared with chemoradiotherapy, anti-angiogenesis agents plus chemoradiotherapy could bring more benefits in terms of short-term efficacy, particularly by notably improving both complete response rate and objective response rate, and overall adverse reactions were acceptable. Anti-angiogenesis agents plus chemoradiotherapy may provide a promising direction for the treatment of locally advanced nasopharyngeal carcinoma.
BACKGROUND: https://inplasy.com/inplasy-2023-8-0076/ , registration number INPLASY202380076.
摘要：
目的：评价抗血管生成药物联合放化疗与放化疗治疗局部晚期鼻咽癌的疗效和安全性。
方法：从成立之日起至2023年4月，在PubMed中系统地搜索了相关文献，Embase,WebofScience,科克伦图书馆,中国国家知识基础设施，中国生物医药,万方和VIP数据库。搜索词包括：鼻咽肿瘤，血管生成抑制剂,Endostar,安洛替尼,阿帕替尼,贝伐单抗,舒尼替尼，帕唑帕尼,放化疗.根据纳入和排除标准对文献进行严格筛选，8项符合条件的研究最终纳入我们的荟萃分析(4项随机对照试验和4项回顾性研究).
结果：共纳入642例患者，抗血管生成药加放化疗组316例,放化疗组326例.我们的荟萃分析结果显示,与放化疗组相比,完全缓解率(RR=1.35，95%CI1.05-1.74，P=0.02)，抗血管生成药物加放化疗组的客观反应率(RR=1.26,95%CI1.12-1.43,P=0.0002)显著提高。在安全方面,抗血管生成药加放化疗组心律失常(RR=3.63,95%CI1.16-11.37,P=0.03)和高血压(RR=1.85,95%CI1.04-3.27,P=0.004)发生率较高,而其他不良反应无统计学差异(均P>0.05)。
结论：与放化疗相比，抗血管生成药物加放化疗可以带来更多的短期疗效方面的好处，特别是通过显著提高完全反应率和客观反应率，总体不良反应可接受.抗血管生成药物联合放化疗可能为局部晚期鼻咽癌的治疗提供有希望的方向。
背景：https://inplasy.com/inplasy-2023-8-0076/，注册号INPLASY202380076。
方法：从成立之日起至2023年4月，在PubMed中系统地搜索了相关文献，Embase,WebofScience,科克伦图书馆,中国国家知识基础设施，中国生物医药,万方和VIP数据库。搜索词包括：鼻咽肿瘤，血管生成抑制剂,Endostar,安洛替尼,阿帕替尼,贝伐单抗,舒尼替尼，帕唑帕尼,放化疗.根据纳入和排除标准对文献进行严格筛选，8项符合条件的研究最终纳入我们的荟萃分析(4项随机对照试验和4项回顾性研究).
结果：共纳入642例患者，抗血管生成药加放化疗组316例,放化疗组326例.我们的荟萃分析结果显示,与放化疗组相比,完全缓解率(RR=1.35，95%CI1.05-1.74，P=0.02)，抗血管生成药物加放化疗组的客观反应率(RR=1.26,95%CI1.12-1.43,P=0.0002)显著提高。在安全方面,抗血管生成药加放化疗组心律失常(RR=3.63,95%CI1.16-11.37,P=0.03)和高血压(RR=1.85,95%CI1.04-3.27,P=0.004)发生率较高,而其他不良反应无统计学差异(均P>0.05)。
结论：与放化疗相比，抗血管生成药物加放化疗可以带来更多的短期疗效方面的好处，特别是通过显著提高完全反应率和客观反应率，总体不良反应可接受.抗血管生成药物联合放化疗可能为局部晚期鼻咽癌的治疗提供有希望的方向。
背景：https://inplasy.com/inplasy-2023-8-0076/，注册号INPLASY202380076。
